Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients

Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients
Real-world data demonstrates the safety, tolerability, and efficacy of Entyvio (vedolizumab) in treating ulcerative colitis (UC) and Crohn’s disease, confirming previous data collected in clinical trials. These findings were the focus of two poster presentations during the recent 25th United European Gastroenterology (UEG) Week in Barcelona, Spain. Entyvio, developed by Japan’s Takeda Pharmaceutical, reduces inflammation in the intestinal mucosa

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Lynn Santaniello says:

    I had constant infections in, & around my med port while on Entyvio !! It did nothing for my Crohn’s in the year and a half of being on it. I had to stop it due to the infections, & my port stopped getting infections.

Leave a Comment

Your email address will not be published. Required fields are marked *